Compounds that increase tissue concentrations of cyclic AMP inhibit the release of histamine from sensitized tissues when they are challenged with antigen. It has been proposed that the anti-asthmatic agent disodium cromoglycate exerts its anti-allergic properties by inhibiting cyclic AMP phosphodiesterase. This hypothesis was based on experiments where it was shown that the inhibition of antigen-induced mast-cell degranulation by isoprenaline and disodium cromoglycate was synergistic (Taylor et al.,
1974)
, and experiments that showed that disodium cromoglycate was a phosphodiesterase inhibitor (Ray & Warren, 1974) .
Compound I.C.I. 74917, Bufrolin (6-n-butyl-2,8-dicarboxy-4,10-dioxo-1,4,7,10-tetrahydro-l,7-phenanthroline) is a potent inhibitor of immediate hypersensitivity reactions in guinea-pig lung and rat mast cells (Evans & Thomson, 1975) . It demonstrates inhibition characteristics in lung similar to those of disodium cromoglycate in mast cells, including the critical time of addition relative to antigen (see Fig. la ) and the development of tolerance (K. J. Barrett-Bee, unpublished work). However, it is active at onehundredth the dose that disodium cromoglycate is active in vitro.
The work described below investigated the allergic release of histamine from guineapig lung and its inhibition by compound I.C.I. 74917 and isoprenaline, alone and in combination, to assess the nature of the inhibition. Chopped lung from actively sensitized guinea-pigs was prepared by our usual method (Barrett-Bee & Green, 1975) and challenged with specific antigen. The resulting release of histamine was inhibited in a dose-dependent manner by compound I.C.I. 74917 and also by isoprenaline (Fig. 2 ). Fig. 1 shows the results of experiments where the time of addition of compound I.C.I. 74917 and DL-isoprenaline (relative to antigen challenge) was varied. Compound I.C.I. 74917 shows a maximal inhibition of histamine release when added with antigen, this is similar to the time-course of inhibition of disodium cromoglycate in rat mast cells (Thomson & Evans, 1975) .
Preincubation of the tissue with DL-isoprenaline at lOOpg/ml for at least 2min before antigen challenge is needed for maximal inhibition (Fig. l a ) presumably to allow a build-up of cyclic AMP. All subsequent experiments used a 3 rnin preincubation.
Dose/response curves for inhibition of histamine release by DL-isoprenaline showed maximal inhibition at 5 ng/ml of isoprenaline a concentration that corresponds approximately to that required for maximum cyclic AMP stimulation (K. J. BarrettBee, unpublished work). The loss of inhibition at high isoprenaline concentrations may be due either to rapid tachyphylaxis or a two-point binding mode for isoprenaline to its p receptor, which at high concentrations of isoprenaline allows dual occupancy of the binding site (the two molecules being bound to different points of the B receptor) and consequent 'self-inhibition'.
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Addition, together with antigen, of compound I.C.I. 74917 (0.1 pg/ml) to chopped sensitized lung, preincubated with DL-isoprenaline for 3 min, resulted in extra inhibition of histamine release as seen in Fig. 2(a) . Comparison of the total inhibition with individual values for compound I.C.I. 74917 and isoprenaline show that there is addition rather than synergism, i.e. if compound I.C.I. 74917 inhibits release by y % then isoprenaline could only act on the remaining (1OO-y)% and inhibit it by x % and vice versa (Fig. 2b) .
It has been shown that compound I.C.I. 74917 is an inhibitor of cyclic AMP phosphodiesterasefromrat mast cells (Barrett-Bee & Henderson, 1976). At theconcentrations used here, however, which were much less than the K, for mast-cell phosphodiesterase, the data indicate that compound I.C.I. 74917 was not acting as a phosphodiesterase inhibitor and potentiating the inhibition by isoprenaline, but it was merely adding to it, i.e. it was acting by a different mechanism.
The experiments shown in Fig. 2 demonstrate that the inhibitions of allergic histamine release by compound I.C.I. 74917 and isoprenaline are independent of each other. This would not be expected if compound I.C.I. 74917 was acting as a phosphodiesterase inhibitor. Any inhibition of histamine release by isoprenaline, caused by its increasing the concentration of cyclic AMP by stimulation of the adenyl cyclase, would be potentiated by the presence of a phosphodiesterase inhibitor. Since potentiation does not occur with compound I.C.I. 7491 7, it seems unlikely, therefore, that the anti-allergic properties of compound I.C.I. 74917 involve its activity as an inhibitor of cyclic AMP phosphodiesterase. Disodium cromoglycate, which itself at a concentration of 5OOpg/ml caused no inhibition of histamine release, increased the total inhibition by isoprenaline (Fig. 2a) . This suggests that, at high concentrations, poor phosphodiesterase inhibitors such as cromoglycate are able to potentiate the inhibition of histamine release by isoprenaline. However, their normal mode of anti-allergic action does not depend upon this property.
Further evidence for this belief is provided by the experiments that indicate that the time ofaddition ofcompound I.C.I. 74917 or disodiumcromoglycaterelative to addition of antigen is critical (Fig. lb) although the drug appeared to be well absorbed in a number of human subjects, the degree of oxidative metabolism varied widely and was a major determinant of responsiveness.
['4C]Debrisoquine hydrochloride was synthesized from Kx4CN labelled in the amidino carbon atom, and rats and male human volunteers were given the drug orally in
